News

SAN DIEGO, CA / ACCESSWIRE / July 28, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO), announced today it has entered into a research collaboration with Syracuse University to further the development [...]

Nascent Biotech CEO Sean Carrick appears on SNN Network to discuss the company developing COVID-19 therapy and vaccine collaboration with Manhattan BioSolutions.  

NEWPORT BEACH, Calif., May 19, 2020 /PRNewswire/ — Hoag Family Cancer Institute and Pickup Family Neurosciences Institute at Hoag, in collaboration with Nascent Biotech, Inc announced today [...]

San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, [...]

As the world of pharma and biotech companies works towards finding a solution for COVID-19, we see a number of different research-oriented companies emerging. Many of these companies specialize [...]

April 7, 2020 San Diego, CA USA. – Nascent Biotech, Inc. (OTCQB: NBIO), today announced that two independent consultants retained by the Company have begun preliminary research on a [...]

March 3, 2020 San Diego, CA USA. – Nascent Biotech, Inc. (OTCQB: NBIO), today announced its intention to begin research on a possible treatment for patients infected with the Coronavirus. [...]

Nascent Biotech founder Dr. Mark C. Glassy will once again be organizing and speaking at the Human Antibodies & Hybridomas conference, held 11-13 November 2020, The Richard Doll Building, [...]

Click each link to download individual publications in PDF format. Brain‐derived neurotrophic factor downregulation in gastric cancer Antibody drug conjugates: Progress, pitfalls, and promises [...]

Nascent Biotech founder Dr. Mark C. Glassy has co-authored a new paper appearing in Human Antibodies entitled, “Antibody drug conjugates: Progress, pitfalls, and promises.” Please [...]